Cash on hand is important to stay afloat and the rest is of little consequence regarding the earnings report announced today. Current shareholders are invested in a company that has reinvented itself with the marketing of Zohydro and investors are looking forward to the future earnings reports. Earnings during the next 3 quarters will be critical and those reports will be the driving force of the stock price. If the future earnings reports reveal profitability, then the stock could be double or triple the current price, trading at $10 or $15 a share during 2014.
The stock just traded at an all time high price, so some investors may take this opportunity to take profits. This has no bearing on the future movement of the stock. My guess is that we double from here to the high teens.
There is increased interest in the company, although the Grifols investment which was not widely noticed has brought delayed justified attention to this highly undervalued equity.
This Is A Beauty Of A Company Stock And We Are Going To Five Dollars A Share Real Quick Here
There were two block trades, so I didn't purchase all 7M shares myself. I read a while back that Fidelity Investments sold their position as a Major Holder from what you currently see listed at Yahoo Finance and a hedge fund got in. There is huge upside to come here and $13 to $15 a share would be no surprise if Zohydro sales take off, which I expect could possibly happen because of acetaminophen which is in other drugs and causes liver damage as you realize.
I apparently need to submit a Schedule 13D to the US Securities and Exchange Commission within 10 days, because earlier today I acquired beneficial ownership of more than 5% of Zogenix which is a publicly traded securities in a public company.
Anyone familiar with that . . . Woohoo!